Stroke can be roughly divided into two categories: ischemic stroke, which accounts for 70% ~ 80% of the total number of stroke patients, mainly including cerebral thrombosis and cerebral embolism; Hemorrhagic stroke accounts for 20% ~ 30% of stroke cases, which can be divided into cerebral hemorrhage and subarachnoid hemorrhage according to different bleeding sites. Stroke is the enemy that harms human health. The prevention and treatment of stroke should be based on the correct choice of drugs and rational use of drugs, and follow the evidence of evidence-based medicine in the treatment to obtain the maximum curative effect with the minimum medical expenses. Commonly used drugs for preventing and treating ischemic stroke are as follows. 1 lipid-lowering drugs dyslipidemia is one of the important risk factors for ischemic stroke and transient ischemic attack. The increase of low density lipoprotein cholesterol (LDL-C) will increase the risk of ischemic stroke. Statins are important drugs for treating hypercholesterolemia and preventing and treating atherosclerotic diseases. Statins are recommended for high-risk stroke patients with normal cholesterol levels and evidence of unstable atherosclerotic plaques to reduce the risk of stroke /TIA. Patients with ischemic stroke /TIA should improve their blood lipid examination as soon as possible. Low density lipoprotein -C2. For patients with 6mmol/L, statins are recommended for treatment, and the blood lipid level should be monitored regularly. For high-risk patients diagnosed with vulnerable atherosclerotic plaque or evidence of arterial embolism, as well as ischemic stroke /TIA with multiple risk factors, it is suggested to strengthen statin therapy and reduce LDL-C to 2, regardless of whether the cholesterol level is elevated. Lower than 65438 0 mmol/L, or lower LDL-C by more than 40%, and regularly monitor the blood lipid level. Existing data show that long-term use of statins is safe. Clinical symptoms and changes of ALT, AST and creatine kinase (CK) should be monitored regularly before and during statin treatment. If the monitoring indicators continue to be abnormal and other influencing factors are excluded, the dosage should be reduced or the drug should be stopped for observation. 2 Anticoagulants Clinically, patients with atrial fibrillation, frequent transient ischemic attack (TIA) or vertebrobasilar artery TIA can consider choosing anticoagulation therapy. Low molecular weight heparin is the first choice for anticoagulation, but it is not suitable for all patients with acute ischemic stroke. All stroke patients need to undergo intracranial and extracranial vascular examination, including rheoencephalogram, angiography or magnetic resonance angiography, CT angiography and so on. Low molecular weight heparin is effective for acute stroke patients with intracranial vascular stenosis. If the patient intends to use warfarin for a long time due to atrial fibrillation, dissecting aneurysm and other reasons. Low molecular weight heparin can be considered. For patients with severe paralysis caused by ischemic stroke who must stay in bed for a long time, attention should be paid to preventing deep venous thrombosis and pulmonary embolism. If there is no bleeding tendency, it is suggested to use low dose subcutaneous anticoagulation to prevent venous thrombosis. Low molecular weight heparin is generally superior to ordinary heparin, but ordinary heparin should be used in patients with severe renal insufficiency. After the clinical diagnosis of cerebral venous thrombosis, we should treat it symptomatically, actively find the cause, and give anticoagulant therapy on the basis of corresponding treatment. Hypertension is the most important risk factor for cerebral hemorrhage and cerebral infarction. Studies have shown that the relative risk of stroke increases by 49% for every increase of systolic blood pressure of 65438±00 mmhg, and by 46% for every increase of diastolic blood pressure of 5mmHg. Effective antihypertensive therapy is very important for the prevention of cerebrovascular diseases. Angiotensin receptor blockers can effectively control blood pressure and reduce the occurrence of stroke in patients with hypertension such as diabetes, atrial fibrillation, left ventricular hypertrophy and carotid endarterectomy. ARB is recommended as a first-line drug to prevent stroke in patients with hypertension. ARBs have good tolerance and compliance, and long-term application is conducive to reducing the occurrence and recurrence of stroke. Long-acting calcium antagonists (CCB) not only have a good antihypertensive effect, but also have a clear anti-atherosclerosis effect. Therefore, long-acting CCB can be used as the first choice for hypertension complicated with atherosclerotic cerebrovascular disease. Patients with acute cerebrovascular disease and severe cerebrovascular stenosis should be carefully treated with antihypertensive therapy. 4 rt-PA drugs should be used in thrombolytic therapy of ultra-early ischemic stroke. Rt-PA is the most effective drug in the treatment of ultra-early cerebral infarction. Evidence-based medicine has proved that intravenous rt-PA thrombolytic therapy is superior to antiplatelet therapy and anticoagulant therapy for patients with acute cerebral infarction who meet the indications. The thrombolytic time window of cerebral infarction in posterior circulation can be appropriately extended. Thrombolytic therapy should be operated by trained doctors in experienced hospitals.